VERICI DX PLC LS-001

Research VERICI DX PLC LS-001 (63V) on Bullrun: market cap EUR 5.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker63V
• ExchangeF
• CountryUnited Kingdom
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyEUR
• Market capEUR 5.53M
• Financial periodFY2024
• RevenueEUR 3.34M
• Revenue growth229.6%
• Net income-EUR 5.87M
• Free cash flow-EUR 6.21M

Valuation Snapshot

latest market cap is EUR 5.53M.

About VERICI DX PLC LS-001

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes;

Frequently asked questions

What is VERICI DX PLC LS-001's market cap?

VERICI DX PLC LS-001's market capitalization is EUR 5.53M.

What does VERICI DX PLC LS-001 do?

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States.